Compare AFLAC Incorporated (AFL) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AFLAC Incorporated vs Humana Inc — how do they compare? AFLAC Incorporated trades at $120.6 (market cap $60.70B), while Humana Inc trades at $388 (market cap $44.77B). The key difference: AFLAC Incorporated is the larger of the two by market cap, and AFLAC Incorporated pays the higher dividend (2.02%). Which is the better fit depends on your goals.
| AFL | HUM | |
|---|---|---|
Market Cap | $60.70B | $44.77B |
Sector | Financials | Health |
52-Week High | $129.55 | $409.42 |
52-Week Low | $103.55 | $163.67 |
Enterprise Value | $70.65B | $52.12B |
Dividend Yield | 2.02% | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFL trades at $120.98, down 0.79% on the day, with a P/E of 13.06 and net income margin of 26.59%. Recent earnings missed estimates for three consecutive quarters, with Q3 2026 results pending. Technical indicators show a bullish overall signal despite bearish moving averages and oscillators. The company maintains a strong dividend history, with recent payouts of $0.61 per share.
Outlook remains mixed; solid profitability and dividend growth support income investors, but earnings misses and revenue declines pose near-term risks. Analyst consensus is cautious with a hold-heavy rating and price target of $118, slightly below current levels. Key catalysts include U.S. sales momentum and Japan unit performance, while currency headwinds and medical cost inflation are concerns.
Humana (HUM) trades at $388.96, up 0.9% with a neutral technical signal. The stock shows strong revenue growth reaching $129.7B in 2025 but faces margin compression with net income margin declining to 0.88%. Recent earnings beat expectations for three consecutive quarters, while analyst consensus targets $409.93. The company maintains solid cash flow generation and recently announced key leadership appointments to strengthen its Medicaid business.
Humana presents a mixed outlook with robust revenue expansion offset by margin pressures. Investment opportunity lies in Medicare Advantage growth and cost reduction initiatives, while risks include competitive pressures and regulatory changes in healthcare. Wall Street maintains cautious optimism with 39% buy ratings amid margin recovery challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
